PharmaCyte Biotech (PMCB) Change in Receivables (2010 - 2012)
PharmaCyte Biotech (PMCB) posted quarterly Change in Receivables of -$2581.0 for Q3 2012, up 58.97% year-over-year from -$1623.5 in Q3 2011, and up 75.42% quarter-over-quarter from -$10501.0 in Q2 2012.
PharmaCyte Biotech (PMCB) Change in Receivables (2010 - 2012) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Change in Receivables for 3 consecutive years, with -$2581.0 the latest figure, recorded in Q3 2012.
- In Q3 2012, Change in Receivables rose 58.97% year-over-year to -$2581.0; the TTM figure through Apr 2013 stood at -$2581.0 (down 138.17% YoY), while the FY2013 annual figure was -$2581.0, down 138.17% from the prior year.
- Change in Receivables improved to -$2581.0 in Q3 2012 per PMCB's latest filing, from -$10501.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $18976.0 in Q2 2011 and bottomed at -$17317.0 in Q1 2011.
- Historically, Change in Receivables has averaged $361.11 across 3 years, with a median of -$2581.0 in 2012.
- On a YoY basis, Change in Receivables climbed as much as 249.1% in 2011 and fell as far as 203.35% in 2011.
- PharmaCyte Biotech's Change in Receivables stood at -$8677.0 in 2010, then jumped by 249.1% to $12937.0 in 2011, then slumped by 119.95% to -$2581.0 in 2012.
- Business Quant data shows PMCB's Change in Receivables at -$2581.0 in Q3 2012, -$10501.0 in Q2 2012, and $10617.0 in Q1 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 31.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 37.16 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 94.29 Mn |
| 10 | PharmaCyte Biotech | 4.30 Mn | 4.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2012 | -2,581.00 |
| Jul 31, 2012 | -2,581.00 |
| Apr 30, 2012 | -10,501.00 |
| Apr 30, 2012 | -10,501.00 |
| Jan 31, 2012 | 10,617.00 |
| Jan 31, 2012 | 10,617.00 |
| Oct 31, 2011 | 12,937.00 |
| Oct 31, 2011 | 12,937.00 |
| Jul 31, 2011 | -6,291.00 |
| Jul 31, 2011 | -6,291.00 |
| Apr 30, 2011 | 18,976.00 |
| Apr 30, 2011 | 18,976.00 |
| Jan 31, 2011 | -17,317.00 |
| Jan 31, 2011 | -17,317.00 |
| Oct 31, 2010 | -8,677.00 |
| Oct 31, 2010 | -8,677.00 |
| Jul 31, 2010 | 6,087.00 |
| Jul 31, 2010 | 6,087.00 |